Skip to content
Menu

Citigroup Maintains Buy on ProKidney, Lowers Price Target to $8

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $10 to $8.

Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $10 to $8.

Read at benzinga.com

← All stock news